1. Market Research
  2. > Biotechnology
  3. > Genomics Market Trends

Analysis of the Western European Biomarkers Market in Drug Discovery and Development

  • June 2014
  • 153 pages
  • Frost & Sullivan
Report ID: 2171914

Summary

Table of Contents

Increasing Applications of Biomarkers are Driving Growth

Biomarkers will certainly change the way healthcare is provided. They are being increasingly used in early drug development and for clinical use as well, boosting their demand. The penetration of biomarkers in various therapeutic applications, the impact of market trends and dynamics are analysed in this study. This research service offers market overview, Market Engineering measurements, revenue forecasts, company profiling and key trends for the market and its segments, namely, genomics, proteomics, metabolomics and imaging biomarkers.

Methodology

-The information contained in this research service was derived from a variety of relevant primary and secondary information sources.
-Primary interviews were conducted with leading tier 1 and tier 2 companies and industry stakeholders, such as key clinicians, the research and development (R&D) community, heads of business development, laboratory personnel and key opinion leaders.
-Secondary data sources include government and public health organisation Websites, the World Health Organization (WHO), the European Medicines Agency (EMA), U.S. Food and Drug Administration (FDA) publications, annual reports, investor presentations, press releases, government public sources, pharmaceutical industry databases and published articles in scientific and medical journals.
-For the total biomarkers and segments, revenue forecasting is performed using a robust, data-driven approach. Current trends, products, technologies and emerging trends have been taken into account, and aggregate figures are provided.
For Market Engineering research, Frost & Sullivan uses tried and tested marketing techniques to provide structure to the research and an easy format to compare results across different countries and markets over time. This project was carried out using primary (telephone or face-to-face interviews) and secondary (published and online material) research as the principle methods of data gathering. The focus of the interviews for this project was primarily the respondent types outlined below.
-Industry participants
-End users
-Key regulatory bodies
-Frost & Sullivan published research services
-Decision support databases
-Country industry forecasts
-Proprietary databases

Key Findings

-The Western European biomarkers market in drug discovery and development will continue to grow - from $ million in 2013 to $ million in 2019, at a compound annual growth rate (CAGR) of % from 2013 to 2020.The use of biomarker-based tests in drug discovery, early diagnosis and prognosis is in the growth stage.
-Advancements in multiplexing will lead to the development of biomarker panels with a higher clinical value. The discovery of biomarkers from samples like urine, breath and saliva, as well as the development of noninvasive tests, will find increased application in infectious disease and cancer testing, in which repeat studies are needed to be able monitor the diseases.
-The development of multi-biomarker panels that can be used to provide accurate predictive value is important, and companies are working towards discovering and integrating results from different discovery platforms to build such panels.
-The adoption of genomics- and proteomics-based biomarkers is currently the highest, with a number of novel lipidomics and immunomics markers also coming to the fore.
-Complex diseases with unmet needs are the major potential areas for biomarker development. Traumatic brain injury (TBI), cardiovascular diseases and autoimmune diseases are some of the areas witnessing quality R&D of novel biomarker-based tests.
-Various European Governments and health authorities are focussing on investing their funding in biomarker R&D. Various knowledge networks and consortia have been formed to help this cause. The U.K. Biobank, the Biomarkers Consortium and the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) E-Register of Studies are some examples.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Cancer Biomarkers Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

  • $ 5795
  • Industry report
  • May 2017
  • by Transparency Market Research

Global Cancer Biomarkers Market: Overview Biomarkers are the substance or molecules found in blood, other body fluids or tissues which states the normal and abnormal condition of the body, biomarkers ...

Next-Generation Sequencing (NGS) Market by Product (Hiseq, Miseq, Hiseq X Ten/X Five, NextSeq500, Ion Proton, PGM, Ions5, PacBio RSII), Services (Targeted, RNA, Exome, De Novo), & Application (Diagnostics, Biomarker, Agriculture) - Global Forecasts to 202

  • $ 5650
  • Industry report
  • April 2017
  • by MarketsandMarkets

The global next-generation sequencing market is estimated to register a CAGR of 20.5% from 2017 to 2022 to reach USD 12.45 billion by 2022. Factors such as technological advancements in NGS platforms, ...

Cancer Biomarker Market Analysis By Type (Breast, Prostate, Colorectal, Cervical, Liver, Lung Cancer), By Biomolecule (Genetic, Epigenetic, Metabolic, Proteomic), By Application, And Segment Forecasts, 2014 - 2025

  • $ 4950
  • Industry report
  • May 2017
  • by Grand View Research

The global cancer biomarkers market is expected to reach a value of USD 33.7 billion by 2025, based on a new report by Grand View Research, Inc. Growing initiatives for development of drugs targeting novel ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.